Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma☆
To access this article, please choose from the options below
☆ SVR has received research support for the conduct of clinical trials at Mayo Clinic from Celgene Corp and Millennium Pharmaceuticals, Ltd. RAK has received consulting fees from Novartis Pharmaceuticals Corp, Celgene Corp, Millennium Pharmaceuticals, Ltd, Aeterna Zentaris Inc, and NeoRx Corp.
PII: S0268-960X(07)00003-3
doi:10.1016/j.blre.2007.01.002
© 2007 Elsevier Ltd. All rights reserved.
